Stockreport

Viridian Therapeutics' stock jumps after Phase III trial met all endpoints [Yahoo! Finance]

Viridian Therapeutics, Inc.  (VRDN) 
PDF Previously known as VRDN-001, veligrotug won in the Phase III THRIVE trial (NCT05176639). It also boasted positive safety data in patients with TED, which is also known [Read more]